Form 8-K/A

8-K/A — Edgewise Therapeutics, Inc.

Accession: 0001104659-26-084088

Filed: 2026-07-16

Period: 2026-07-10

CIK: 0001710072

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Financial Statements and Exhibits

Documents

8-K/A — tm2620181d2_8ka.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (tm2620181d2_ex99-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K/A — FORM 8-K/A

8-K/A (Primary)

Filename: tm2620181d2_8ka.htm · Sequence: 1

false

0001710072

2026-07-10

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K/A

(Amendment No. 1)

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event

reported):

July 10, 2026

Edgewise Therapeutics, Inc.

(Exact name of registrant as specified in its

charter)

Delaware

001-40236

82-1725586

(State or other jurisdiction

of incorporation)

(Commission File Number)

(IRS

Employer

Identification No.)

1715

38th St.

Boulder,

CO 80301

(Address of principal executive offices) (Zip Code)

(720)

262-7002

(Registrant’s telephone number, including

area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended

to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.

below):

Written communications pursuant to Rule 425 under the

Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the

Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b)

under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c)

under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol(s)

Name

of each exchange on which registered

Common

Stock, $0.0001 par value per share

EWTX

The

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth

company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange

Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant

has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant

to Section 13(a) of the Exchange Act. ¨

Explanatory Note

On July 13,

2026, Edgewise Therapeutics, Inc. (the “Company”) filed a Current Report on Form 8-K (the “Initial Report”)

with the Securities and Exchange Commission to report, among other things, the completion of the acquisition of the Company’s

sevasemten compound and certain other related assets collectively constituting the Company’s muscular dystrophy program by Servier

Pharmaceuticals LLC and Les Laboratoires Servier (together, the “Buyers”, and such transaction, the “Transaction”),

pursuant to the terms and conditions of the previously announced Asset Purchase Agreement by and among the Company and the Buyers.

This Current Report on Form 8-K/A is being filed solely to

amend the Initial Report to include the pro forma financial information required by Item 9.01(b) of Form 8-K. This Current Report

on Form 8-K/A should be read in conjunction with the Initial Report, which provides a more complete description of the Transaction.

Item 9.01 Financial Statements and Exhibits

(b) Pro forma financial information.

The unaudited pro forma condensed financial information required by

Item 9.01(b) of Form 8-K is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

(d) Exhibits:

Exhibit No.

Description

99.1

Unaudited pro forma condensed financial information

104

Cover Page Interactive Data File (embedded within the Inline XBRL documents)

SIGNATURES

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EDGEWISE THERAPEUTICS,

INC.

By:

/s/

Michael Nofi

Michael

Nofi

Chief

Financial Officer

Date: July 16, 2026

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: tm2620181d2_ex99-1.htm · Sequence: 2

Exhibit 99.1

EDGEWISE THERAPEUTICS, INC.

UNAUDITED PRO

FORMA CONDENSED FINANCIAL INFORMATION

On May 31, 2026, Edgewise Therapeutics, Inc. (“Edgewise”

or the “Company”) entered into a definitive Asset Purchase Agreement (the “APA”) with Servier Pharmaceuticals

LLC and Les Laboratoires Servier (together, “Servier” or the “Buyers”), pursuant to which Servier acquired the

Company's sevasemten muscular dystrophy program, including the related intellectual property, know-how, select employees, contracts, regulatory

filings and clinical data (the “Transaction”). On July 10, 2026, the Company completed the Transaction. Following the

closing of the Transaction, Edgewise is a cardiovascular-focused company, with a pipeline comprised of EDG-7500, EDG-15400 and EDG-003.

Under the terms of the APA, the Company received $1.55 billion in upfront cash consideration and is eligible to receive up to $1.1 billion

in additional regulatory and commercial milestone payments, for aggregate potential consideration of up to $2.65 billion.

The disposed assets do not meet the definition of a business under

U.S. generally accepted accounting principles ("U.S. GAAP"). Accordingly, the Transaction is accounted for as a sale of nonfinancial

assets. Because the Transaction constitutes a significant disposition for purposes of Item 2.01 of Form 8-K, the Company has prepared

the following unaudited pro forma condensed financial information in accordance with Article 11 of Regulation S-X. The unaudited

pro forma condensed balance sheet as of March 31, 2026 gives effect to the Transaction as if it had occurred on March 31, 2026.

The unaudited pro forma condensed statements of operations for the three months ended March 31, 2026 and for the year ended December 31,

2025 give effect to the Transaction as if it had occurred on January 1, 2025, the beginning of the earliest period presented.

The unaudited pro forma condensed financial information is derived

from, and should be read together with, the Company’s audited financial statements, related notes and “Management’s

Discussion and Analysis of Financial Condition and Results of Operations” for the year ended December 31, 2025 included in

its Annual Report on Form 10-K filed February 26, 2026, and its unaudited condensed financial statements, related notes and

“Management’s Discussion and Analysis of Financial Condition and Results of Operations” as of and for the three months

ended March 31, 2026 included in its Quarterly Report on Form 10-Q filed May 7, 2026.

The pro forma adjustments are based on currently available information

and certain assumptions that management believes are reasonable. The historical financial information has been adjusted to give effect

to transaction accounting adjustments include all necessary transaction accounting adjustments, including those that are not expected

to have a continuing impact. The transaction accounting adjustments giving effect to the sale of the sevasemten program in the unaudited

pro forma condensed financial information include:

· the receipt of $1.55 billion of upfront cash consideration payable at closing

under the APA;

· the derecognition of the assets and liabilities of the disposal group transferred

to, and assumed by, Servier;

· the recognition of the estimated gain on the sale;

· the elimination of operating expenses and personnel-related costs directly

attributable to the sevasemten program that will not continue following the Transaction;

· the estimated income tax effect of the Transaction and of the pro forma adjustments;

· the net impact of the Transition Services Agreement entered into with Servier;

and

· estimated transaction-related employee separation and related benefit costs.

The upfront cash consideration reflects the amount payable at closing.

The up to $1.1 billion of contingent regulatory and commercial milestones is excluded from the pro forma gain, as it remains constrained

for recognition purposes until it is probable that a significant reversal will not occur, a threshold not met for milestones dependent

on future approvals or sales outside the Company's control. The unaudited pro forma condensed financial information does not reflect any

anticipated cost savings, dis-synergies or other operating efficiencies that may result from the Transaction, and is not necessarily indicative

of the results of operations or financial position that would have been achieved had the Transaction occurred on the dates indicated,

nor is it indicative of future results. Actual amounts could differ materially from these estimates.

EDGEWISE THERAPEUTICS, INC.

UNAUDITED PRO FORMA CONDENSED BALANCE SHEET

AS OF MARCH 31, 2026

(In thousands, except share and per share data)

(Unaudited)

Edgewise

Historical

(As Reported)

Transaction

Accounting

Adjustments

Note

Pro Forma

Assets

Current assets

Cash and cash equivalents

$ 33,211

1,499,220

(A), (G)

1,532,431

Marketable securities, available for sale

466,351

Prepaid expenses and other assets

10,230

(4,055 )

(B)

6,175

Total current assets

509,792

1,495,165

2,004,957

Property and equipment, net

7,396

Operating lease right-of-use asset

1,334

Total assets

518,522

1,495,165

2,013,687

Liabilities and stockholders’ equity

Current liabilities

Accounts payable

$ 7,293

(4,310 )

(B)

2,983

Accrued compensation

5,678

(780 )

(G)

4,898

Accrued other expenses

8,555

(5,246 )

(B)

3,309

Operating lease liability, current portion

1,017

Income taxes payable

225,856

(E)

225,856

Deferred income – transition services, current portion

5,364

(F)

5,364

Total current liabilities

22,543

220,884

243,427

Operating lease liability, net of current portion

2,776

Deferred income – transition services

12,516

(F)

12,516

Total liabilities

25,319

233,400

258,719

Commitments and contingencies

Stockholders’ equity:

Preferred stock, $.0001 par value per share; 200,000,000 shares authorized and no shares issued or outstanding as of March 31, 2026

Common stock, $.0001 par value per share; 1,000,000,000 shares authorized as of March 31, 2026; 107,481,522 shares shares issued and outstanding as of March 31, 2026

Additional paid-in capital

1,088,829

Accumulated other comprehensive income (loss)

(252 )

(Accumulated deficit) / retained earnings

(595,384 )

1,261,765

(C)

666,381

Total stockholders’ equity

493,203

1,261,765

1,754,968

Total liabilities and stockholders’ equity

$ 518,522

1,495,165

2,013,687

See accompanying notes to unaudited pro forma

condensed financial information.

EDGEWISE THERAPEUTICS, INC.

UNAUDITED PRO FORMA CONDENSED STATEMENT OF

OPERATIONS

THREE MONTHS ENDED MARCH 31, 2026

(In thousands, except share and per share data)

(Unaudited)

Edgewise

Historical

(As Reported)

Transaction

Accounting

Adjustments

Note

Pro Forma

Operating expenses

Research and development

$ 42,651

(15,946 )

(D), (F)

26,705

General and administrative

11,464

(1,554 )

(D), (F)

9,910

Total operating expenses

54,115

(17,500 )

36,615

Loss from operations

(54,115 )

17,500

(36,615 )

Other income

Interest income

5,102

Other income

3,576

(F)

3,576

Total other income

5,102

3,576

8,678

Net loss

(49,013 )

21,076

(27,937 )

Other comprehensive income (loss):

Unrealized gain on available-for-sale securities, net

(929 )

Total comprehensive loss

$ (49,942 )

21,076

(28,866 )

Net loss per share, basic and diluted

$ (0.46 )

(0.27 )

Weighted-average shares outstanding, basic and diluted

107,116,709

See accompanying notes to unaudited pro forma

condensed financial information.

EDGEWISE THERAPEUTICS, INC.

UNAUDITED PRO FORMA CONDENSED STATEMENT OF

OPERATIONS

YEAR ENDED DECEMBER 31, 2025

(In thousands, except share and per share data)

(Unaudited)

Edgewise

Historical

(As Reported)

Transaction

Accounting

Adjustments

Note

Pro Forma

Operating expenses

Research and development

$ 151,389

(57,852 )

(D), (F)

93,537

General and administrative

40,017

(3,388 )

(D), (F)

36,629

Total operating expenses

191,406

(61,240 )

130,166

Loss from operations

(191,406 )

61,240

(130,166 )

Other income

Interest income

23,611

Other income

14,304

(F)

14,304

Gain on sale of sevasemten program

1,487,621

(C)

1,487,621

Total other income

23,611

1,501,925

1,525,536

Net income (loss) before income taxes

(167,795 )

1,563,165

1,395,370

Income tax expense / (benefit)

259,843

(E)

259,843

Net income (loss)

(167,795 )

1,303,322

1,135,527

Other comprehensive income (loss):

Unrealized gain on available-for-sale securities, net

257

Total comprehensive income (loss)

$ (167,538 )

1,303,322

1,135,784

Net earnings (loss) per share, basic and diluted

$ (1.63 )

11.03

Weighted-average shares outstanding, basic and diluted

102,930,744

See accompanying notes to unaudited pro forma

condensed financial information.

EDGEWISE THERAPEUTICS, INC.

NOTES TO UNAUDITED PRO FORMA CONDENSED FINANCIAL

INFORMATION

(In thousands, unless disclosed otherwise)

(Unaudited)

Note 1 — Basis of Presentation

The unaudited pro forma condensed financial information has been prepared

in accordance with Article 11 of Regulation S-X. The historical financial information has been adjusted to give effect to transaction

accounting adjustments include all necessary transaction accounting adjustments, including those that are not expected to have a continuing

impact. The sevasemten program has historically been an in-process research and development program and the Company expenses research

and development costs as incurred and, accordingly, sevasemten carries no capitalized intangible or in-process research and development

balance on the historical balance sheet. The operations of the disposal group did not meet the criteria to be presented as discontinued

operations. Amounts are presented in thousands unless otherwise noted.

Note 2 — Transaction Accounting Adjustments

(A) Upfront Cash Proceeds — Reflects the receipt

of $1,550,000 of upfront cash consideration payable at closing under the APA, less $50,000 of estimated transaction costs directly attributable

to the Transaction and paid at closing and less $780 of transaction-related employee payments the Company remains obligated to settle

at closing (see note (G)), resulting in a net increase in Cash and cash equivalents of $1,499,220. The estimated transaction costs are

also reflected as a reduction of the gain on sale (see note (C)). Amounts that may be earned in the future under the milestone provisions

are excluded from the pro forma adjustments.

(B) Derecognition of Net Liabilities Assumed — Reflects

the derecognition of the assets and liabilities of the disposal group transferred to, and assumed by, Servier under the APA. The disposal

group comprises prepaid expenses and other assets, accounts payable and accrued other expenses. Because the sevasemten intellectual property,

know-how, regulatory filings, clinical data and related contracts were internally generated and the related costs were expensed as incurred,

no intangible asset is derecognized. The following table summarizes the carrying value of the assets disposed and liabilities assumed

in connection with the Transaction:

(in thousands)

As of March 31, 2026

Prepaid expenses and other assets

$ 4,055

Total Assets

4,055

Accounts payable

4,310

Accrued other expenses

5,246

Total Liabilities

9,556

Net Liabilities

$ 5,501

estimated $1,487,621 gain on the Transaction, directly attributable to and resulting from the sale of sevasemten to Servier. The gain

is calculated as the upfront cash consideration, plus the carrying amount of net liabilities assumed by Servier, less the carrying amount

of assets transferred and directly attributable transaction costs, as set forth in the table below. The gain is further reduced by the

portion of the total consideration allocated to the Company's below-market transition services obligation, which is deferred as a transition

services liability and recognized as the related services are performed, rather than recognized in the gain at closing (see note (F)).

The gain is nonrecurring and is not expected to have a continuing impact on the Company's operations. Because the pro forma statement

of operations for the year ended December 31, 2025 assumes the Transaction occurred on January 1, 2025, the same estimated gain

is presented as a separate line item in that statement of operations and is reflected within the accumulated deficit (retained earnings)

balance in stockholders' equity on the pro forma balance sheet as of March 31, 2026.

Gain on Sale of Sevasemten Program

(in thousands)

Upfront cash consideration received at closing

$ 1,550,000

Add: Carrying amount of total liabilities of the disposal group assumed by Servier

9,556

Less: Carrying amount of assets of the disposal group transferred to Servier

4,055

Less: Estimated transaction costs directly attributable to the Transaction

50,000

Less: Consideration allocated to the transition services obligation

17,880

Gain on sale of sevasemten program before income taxes

1,487,621

Less: Estimated income tax effect (see note (E))

225,856

Gain on sale of sevasemten program, net of income taxes

$ 1,261,765

(D) Elimination of Divested Operating Expenses — Reflects

the elimination of operating expenses directly attributable to the sevasemten program that will not continue following the Transaction,

as summarized in the table below. The eliminated expenses comprise (i) external clinical program costs directly attributable to the

divested program and (ii) internal personnel-related costs associated with employees who directly support the muscular dystrophy

business and who were separated from the Company at the time of the Transaction and may transfer to Servier.

Eliminated operating expenses

(in thousands)

Three months ended

March 31, 2026

Year ended December

31, 2025

Research and development

$ 18,939

$ 69,821

General and administrative

2,137

5,723

Total operating expenses

$ 21,076

$ 75,544

(E) Income Tax Effect — Reflects the estimated income

tax effect of the Transaction and of the pro forma adjustments. Although the Company maintains a full valuation allowance against its

deferred tax assets, the estimated taxable gain on the Transaction exceeds the federal and state net operating loss carryforwards and

tax credits available to offset it after giving effect to the annual limitations imposed under Section 382 of the Internal Revenue

Code. No income tax adjustment is reflected in the pro forma statement of operations for the three months ended March 31, 2026, as

the Company is projected to be in a pre-tax loss position for the period. The income tax expense reflected in the pro forma statement

of operations (which gives effect to the Transaction as of January 1, 2025) differs from the income taxes payable reflected in the

pro forma balance sheet (which gives effect to the Transaction as of March 31, 2026) because each is computed using the taxable income,

net operating loss carryforwards and tax attributes available as of the respective assumed transaction date. These amounts are preliminary

and subject to change based on the Company's actual results for the period and finalization of the related income tax provision.

(F) Transition Services Agreement — In connection

with the Transaction, and effective at closing, the Company and Servier entered into a Transition Services Agreement (the "TSA")

under which the Company will provide specified transitional services to Servier for a period of time following closing. Under the TSA,

Servier reimburses the Company for 50% of the FTE costs and 50% of the out-of-pocket third-party costs the Company incurs in performing

the services (other than costs under the purchased contracts, which Servier reimburses in full until those contracts transfer). The TSA

has an initial term of at least 18 months following closing and may extend to the first marketing approval of sevasemten (including any

supplemental approvals for Duchenne muscular dystrophy) or completion of all service periods, with individual services extendable for

one additional six-month period.

Because Servier reimburses only 50% of the Company's cost of performing

the services, a portion of the total consideration received in the Transaction is attributable to the Company's obligation to provide

those services at below-market rates. That portion, estimated at $17,880, is not recognized in the gain at closing (see note (C)). Instead

it is recorded as a deferred income – transition services liability and released to income as the related services are performed.

Of this amount, $5,364 is expected to be recognized within twelve months and is classified as current, with the remaining $12,516 classified

as non-current.

The pro forma statements of operations reflect the TSA on a gross basis:

the full cost of performing the services is presented within operating expenses in its natural classification (research and development

and general and administrative), and the cash reimbursements from Servier, together with the release of the deferred income liability,

are presented within Other income. The pro forma effect of the TSA on the statements of operations is summarized below:

(in thousands)

Three months ended

March 31, 2026

Year ended December

31, 2025

Cost of transition services (in operating expense)

$ (3,576 )

$ (14,304 )

Reimbursements from Servier (50% of costs) — other income

1,788

7,152

Release of deferred income – transition services — other income

1,788

7,152

Net effect on net income (loss)

$ -

The estimated TSA amounts presented reflect only the periods presented

and are not necessarily indicative of the costs, reimbursements, or net charges the Company will incur under the TSA in periods after

March 31, 2026. The net impact in future periods is expected to vary based on the level of services requested by Servier and to decline

as the transition services wind down.

(G) Transaction-Related Employee Separation Costs — Pursuant

to the APA, the Company remains responsible for settling $780 of previously accrued employee obligations (accrued annual bonuses and accrued

paid time off) relating to employees who were separated from the Company at the time of the Transaction and may transfer to Servier. Because

these amounts were already accrued in the historical financial statements, their settlement does not represent an incremental charge to

results of operations. The obligation is reflected as a decrease to accrued compensation of $780, with a corresponding reduction of cash

and cash equivalents (see note (A)), in the pro forma condensed balance sheet as of March 31, 2026.

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.1

Cover

Jul. 10, 2026

Cover [Abstract]

Document Type

8-K/A

Amendment Flag

false

Document Period End Date

Jul. 10, 2026

Entity File Number

001-40236

Entity Registrant Name

Edgewise Therapeutics, Inc.

Entity Central Index Key

0001710072

Entity Tax Identification Number

82-1725586

Entity Incorporation, State or Country Code

Entity Address, Address Line One

1715

38th St.

Entity Address, City or Town

Boulder

Entity Address, State or Province

Entity Address, Postal Zip Code

80301

City Area Code

720

Local Phone Number

262-7002

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

Stock, $0.0001 par value per share

Trading Symbol

EWTX

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration